Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLP Peanut in Healthy Subjects and Subjects With Peanut Allergy
NCT05476497Phase 1Active, not recruiting
- Sponsor
- Allergy Therapeutics PLC
- Start
- Oct 2022
- Primary completion
- Nov 2026
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Polyvac Peanut in peanut allergy (4 arms), sponsored by Allergy Therapeutics PLC. Primary endpoints: Number and severity of Adverse Events at 3 days and Number of subjects discontinuing prematurely from treatment due to AEs at 15 weeks. Started Oct 2022; status: active, not recruiting.
02
Drugs
Polyvac Peanut
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT05476497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05476497.